Systematic review of ixabepilone for treating metastatic breast cancer

Li, Jing; Ren, Jing; Sun, Weijian

doi:10.1007/s12282-016-0717-0

Cited by 28 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4][5][6][7] Furthermore, other widely used drugs in this setting are vinorelbine, gemcitabine, ixabepilone (not approved by European Medicines Agency), nab-paclitaxel (where available) and liposomal anthracyclines. [8][9][10][11][12] Eribulin mesylate is an irreversible, non-taxane, microtubule growth inhibitor with a novel mechanism of action, also capable to overcome taxane resistance. 13 14 On the basis of the results of phase III trials, study 305 (EMBRACE) in which median overall survival (OS) was significantly longer with eribulin compared with the treatment of physician's choice (13.1 vs 10.6 months, p=0.041) and study 301, and the pooled analysis of both aforementioned trials, 7 15 16 eribulin was approved in the USA (November 2010) and in Europe (March 2011) for the treatment of MBC previously treated with at least two lines of chemotherapy, including anthracyclines and taxanes, and with at least one chemotherapy regimen, respectively.…”

Section: Key Questionsmentioning

confidence: 99%

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

et al. 2017

View full text Add to dashboard Cite

BackgroundOn the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, and at least one chemotherapeutic regimen for metastatic disease.MethodsIn our study, we investigated the efficacy and tolerability of eribulin as second or further line chemotherapy in 137 women affected by aBC.ResultsEribulin as monotherapy provided benefit in terms of progression-free survival (PFS), response rate (RR) and disease control rate (DCR) independently of its use as second or late-line therapy. The overall RR and DCR were 17.5% and 64%, respectively. In particular, DCR and overall RR were 50% and 13.6%, 65.4% and 21.1%, 70.4% and 14.8% and 66.7% and 16.7% in second, third, fourth and further lines of treatment, respectively. Median PFS (mPFS) according to the line of therapy was 5.7, 6.3, 4.5 and 4.0 months in patients treated with eribulin in second, third, fourth and over the fourth line, respectively. No significant difference in terms of mPFS was found between the various BC subtypes. Overall, eribulin resulted safe and most adverse events were of grade 1 or 2 and easily manageable. Grades 3–4 toxicities were neutropaenia and neurotoxicity.ConclusionsWith the limitations due to the observational nature of our findings, eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with aBC.

show abstract

Section: Key Questionsmentioning

confidence: 99%

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Its analogue, lenalidomide is also routinely used in hematological malignancies. Eribulin is a synthetic analogue of halichondrin B produced by the marine sponge Halichondria okadai and a relatively newer anticancer agent providing promising anticancer effect in metastatic breast cancer …”

Section: Introductionmentioning

confidence: 99%

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Islam

Lustberg

Staff

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally invasive or metastatic breast cancer, respectively. However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events. It is generally perceived that vinca alkaloids and the antiangiogenic agent thalidomide are more neurotoxic, compared to eribulin. The exposure to these chemotherapeutic agents is associated with an axonal, length-dependent, sensory polyneuropathy of mild to moderate severity, whereas it is considered that the peripheral nerve damage, unless severe, usually resolves soon after treatment discontinuation. Advanced age, high initial and prolonged dosing, coadministration of other neurotoxic chemotherapeutic agents and pre-existing neuropathy are the common risk factors. Pharmacogenetic biomarkers might be used to define patients at increased susceptibility of CIPN. Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin. K E Y W O R D S assessment, eribulin, peripheral neurotoxicity, thalidomide, vinca alkaloids

show abstract

“…Во всех данных исследованиях было продемонстрировано превосходство 3-недельного режима относительно ЧОО. По результатам метаанализа [14], достоверных различий в показателях времени до прогрессирования (ВДП) и общей выживаемости (ОВ) не отмечено. Однако в двух наиболее крупных исследованиях 2 фазы [12,13] достигнуто статистически значимое увеличение ВДП на фоне применения 3-недельного режима.…”

Section: иксабепилон при метастатическом раке молочной железыunclassified

“…Важно отметить, что 3-недельный режим введения ассоциировался с более частым развитием нейтропений III и IV ст., однако частота фебрильных нейтропений не превысила 2,2%, в то время как диарея III и IV ст. достоверно чаще отмечалась на фоне еженедельных введений иксабепилона [14]. Различий в частоте других нежелательных явлений, в т. ч. нейропатии, по результатам метаанализа не отмечено.…”

Section: иксабепилон при метастатическом раке молочной железыunclassified

“…Показатели ОВ, доступные в 3 исследованиях с аналогичным дизайном для 2635 больных, оцененные в метаанализе, демонстрируют значимое увеличение медианы в группе комбинированной терапии иксабепилон + капецитабин в сравнении с монотерапией капецитабином (HR -0,91) [14].…”

Section: иксабепилон при метастатическом раке молочной железыunclassified

See 1 more Smart Citation

Ixabepilone: new perspectives for its use in breast cancer

2018

View full text Add to dashboard Cite

Despite significant advances in recent years, the drug therapy for breast cancer (BC) is still based on chemotherapy. The introduction of new effective cytostatic agents with a favorable toxicity profile is likely to remain an urgent objective for modern pharmacology in oncology. Ixabepilone, first in a new class of antineoplastic agents, the epothilones, has demonstrated high efficacy in the treatment of breast cancer both in its early stages and in patients, who have received 2 or more lines of chemotherapy. The article discusses the results of major studies, as well as the last meta-analysis of Ixabepilone studies in locally advanced and metastatic breast cancer. It presents the results of two large randomized studies of Ixabepilone in adjuvant regimens in patients with early breast cancer with an unfavourable prognosis.

show abstract

Systematic review of ixabepilone for treating metastatic breast cancer

Cited by 28 publications

References 23 publications

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Ixabepilone: new perspectives for its use in breast cancer

Contact Info

Product

Resources

About